Point-Of-Care Molecular Diagnostics Market Report 2026

Point-Of-Care Molecular Diagnostics Market Overview

• Point-Of-Care Molecular Diagnostics market size has reached to $3.98 billion in 2025 • Expected to grow to $7.91 billion in 2030 at a compound annual growth rate (CAGR) of 14.7% • Growth Driver: Rising Incidence Of Infectious And Respiratory Diseases Fueling The Growth Of The Market Due To Increased Need For Rapid Diagnostics • Market Trend: Next-Generation Poc Molecular Diagnostics Technologies Revolutionize Healthcare Industry • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Point-Of-Care Molecular Diagnostics Market?

Point-of-care (POC) molecular diagnostics refers to tests that detect the presence of specific nucleic acids in a clinical specimen, such as feces, saliva, urine, blood, and tissue. This molecular diagnostic is based on seeing targeted portions of microbial genetic material, DNA or RNA. It is utilized by the healthcare sector to detect emergency usage authorization to diagnose diseases. Point-of-care (POC) molecular diagnostic is used to detection of disease antigens or antibodies in human samples, such as mononucleosis, influenza, and group A streptococcus (GAS). The main product and services of point-of-care molecular diagnostics are assays and kits, instruments and analyzers and software and services. Assays and kits refer to the equipment which is used in carrying out analyses such as studying disease pathways. Assays and kits were widely used for detecting rapid and accurate diagnosing and monitoring various diseases. Reverse transcription-polymerase chain reaction (RT-PCR), in situ-hybridization and sequencing are the technologies used in point-of-care molecular diagnostics that are used for diagnosis of diseases such as respiratory diseases, hospital-acquired infections (HAIs), cancer/oncology, hepatitis and hematologic. Decentralized labs, hospitals, home care, and assisted living healthcare facilities use point of care molecular diagnostics.

What Is The Point-Of-Care Molecular Diagnostics Market Growth Forecast?

The point-of-care molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $7.91 billion in 2030 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to increasing adoption of home-based molecular testing, rising investments in rapid diagnostics infrastructure, expansion of respiratory and oncology testing applications, growing integration of cloud-based diagnostic platforms, increasing focus on early disease detection. Major trends in the forecast period include increasing adoption of rapid molecular testing platforms, rising demand for decentralized diagnostic solutions, growing integration of automated sample processing, expansion of syndromic testing panels, enhanced focus on fast turnaround times.

What Is The Driver Of The Point-Of-Care Molecular Diagnostics Market?

The rapid growth in the increasing occurrence of infectious and respiratory diseases is expected to significantly contribute to the growth of the point-of-care molecular diagnostics market. Respiratory infections, such as viruses or bacteria, are caused by microorganisms that influence the respiratory system. These microbes can be transferred through coughing, sneezing, or direct touch. The severity of the respiratory medications includes a variety of inhalers, oral medications, intravenous treatments, and point-of-care molecular diagnostic to cure the patient. For instance, in June 2024, according to the UK Health Security Agency, a UK-based government agency, between week 40 of 2022 and week 15 of 2023, 108 NHS trusts in England reported 1,681 critical care admissions for confirmed influenza. In comparison, the previous season saw 182 admissions across 114 trusts, increasing to 316 by week 39 of 2022. Therefore, the rapid occurrence of infectious and respiratory diseases and death will drive the point-of-care-molecular diagnostics market.

Key Players In The Global Point-Of-Care Molecular Diagnostics Market

Major companies operating in the point-of-care molecular diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, BioMérieux SA, Hologic Inc, Becton Dickinson and Company, Siemens Healthineers AG, QuidelOrtho Corporation, Bio Rad Laboratories Inc, Qiagen N V, Biocartis Group NV, DiaSorin S p A, SD Biosensor Inc, Cue Health Inc, Visby Medical Inc, Binx Health Inc, Molbio Diagnostics Pvt Ltd, Credo Diagnostics Biomedical Pvt Ltd, Genetron Health, Mammoth Biosciences Inc, Seegene Inc

Global Point-Of-Care Molecular Diagnostics Market Trends and Insights

Major companies operating in the point-of-care molecular diagnostics market are focused on providing technologically advanced solutions to strengthen their market position. These companies are implementing next-generation point-of-care molecular diagnostics technologies solutions and related services, such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, DNA microarrays, and others to implement on POC devices with features of accelerating analysis times and lowering costs. For instance, In May 2023, Sensible Diagnostics, a US-based diagnostics company, launched a 10-minute point-of-care PCR system. Sensible Diagnostics is utilizing the experience Curative has gained with its diagnostics business during the pandemic. The firm said it has run more than two million molecular point-of-care COVID-19 tests, and its PCR platform has a 10-minute time-to-result.

What Are Latest Mergers And Acquisitions In The Point-Of-Care Molecular Diagnostics Market?

In July 2024, Roche Holding AG., a Switzerland-based global healthcare company that develops medicines, treatments, and diagnostics, acquired LumiraDx Ltd. for an undisclosed amount. With this acquisition, Roche Holding AG. aims to enhance its diagnostics portfolio, improve access to decentralized healthcare solutions, and expand testing capabilities, particularly in underserved regions. LumiraDx Ltd., a UK-based diagnostic company developing innovative point-of-care (POC) testing solutions.

What Defines the Point-Of-Care Molecular Diagnostics Market?

The point-of-care (POC) molecular diagnostics market includes revenues earned by AAT, antigen, or antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Point-Of-Care Molecular Diagnostics Market Report 2026?

The point-of-care molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care molecular diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.